SANA
Sana Biotechnology Inc
2.70$
-1.1%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
Sana Biotechnology Inc (SANA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -33 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -34 | -30 | -33 | -38 | -38 | -50 | -41 | -50 | -110 | -78 | -71 | -65 | -76 | -79 | -59 | -64 | -52 | -66 | -59 | -52 | -47 | -49 | -33 | -29 | -33 | -37 | -33 | -132 | |
| 1.0 | 1.3 | 1.4 | 1.5 | 1.8 | 2.2 | 2.6 | 2.9 | 3.3 | 3.6 | 3.8 | 4.0 | 4.2 | 4.3 | 4.4 | 4.5 | 7.5 | 3.7 | 3.9 | 4.1 | 5.7 | 3.6 | 2.9 | 3.2 | 3.1 | 2.4 | 2.2 | 11 | |
| 0.5 | 0.8 | 1.1 | 1.2 | 2.8 | 4.2 | 4.9 | 6.0 | 7.3 | 7.8 | 9.9 | 10 | 11 | 8.8 | 9.8 | 9.0 | 7.9 | 9.1 | 11 | 11 | 6.4 | 7.0 | 6.6 | 5.5 | 6.3 | 5.7 | 5.3 | 23 | |
| 3.6 | 3.2 | 54 | – | 71 | 132 | -71 | -2.8 | 28 | 5.8 | 3.8 | -1.1 | 17 | 11 | 37 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 4.6 | -1.1 | -0.7 | 5.3 | 2.7 | -3.1 | 8.8 | 5.7 | -1.5 | -3.4 | 4.4 | 12 | -5.6 | -11 | 14 | 5.2 | 10 | -7.5 | 2.3 | -0.3 | 4.3 | -11 | -3.4 | 0.7 | 3.4 | -6.5 | 1.5 | -0.9 | |
| 5.7 | 5.6 | 2.7 | 6.3 | 9.3 | 6.4 | 10 | 8.1 | 5.2 | 7.5 | 4.4 | 4.4 | 4.6 | 2.2 | 1.6 | 2.2 | 14 | 16 | 13 | 4.1 | 0.4 | 0.1 | 0.1 | 0.0 | 0.9 | 0.3 | 1.6 | 2.8 | |
| 27 | 39 | -36 | -268 | 13 | 49 | -35 | -186 | -74 | 13 | 78 | 32 | 88 | 63 | 43 | 51 | 15 | -77 | 5.8 | 42 | 47 | 17 | 7.7 | -48 | -16 | 49 | -88 | -103 | |
| – | – | – | – | – | 627 | 0.3 | 1.6 | -2.2 | 0.7 | 1.6 | 1.6 | -3.3 | 0.2 | – | – | – | – | – | – | – | -0.1 | 0.1 | – | -0.1 | – | 3.7 | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -0.1 | – | – | – | -0.1 | – | – | |
| 7.8 | 0.0 | 436 | 0.0 | 0.1 | 627 | 0.3 | 1.6 | 3.1 | 0.7 | 1.6 | 1.6 | 1.1 | 0.2 | 30 | 0.2 | 1.7 | 186 | 11 | 2.1 | 0.6 | 1.0 | 0.6 | 110 | 18 | -0.1 | 94 | 221 | |
| 0.8 | 9.6 | 366 | -306 | -24 | 626 | -76 | -235 | -181 | -65 | 7.8 | -31 | 13 | -16 | 13 | -12 | -35 | 44 | -42 | -8.0 | 0.6 | -31 | -25 | 32 | -31 | 12 | -27 | -14 | |
| -40 | -35 | -36 | -44 | -47 | -56 | -51 | -59 | -115 | -85 | -76 | -69 | -81 | -81 | -60 | -66 | -66 | -81 | -72 | -56 | -48 | -49 | -33 | -29 | -34 | -38 | -34 | -135 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.